Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 7,384 matching trials from the live ClinicalTrials.gov search.
Filters: "major depressive disorder" Clear all
Completed Not applicable Interventional Results available

Prolonged Exposure Therapy for PTSD and Opioid Use Disorder

NCT04104022
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Prolonged Exposure Therapy, Attendance-based monetary incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Not applicable Interventional

Coil Positioning in Navigated Transcranial Magnetic Stimulation Feasibility in Depression Patients Trial

NCT03795051
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Navigated Transcranial Magnetic Stimulation
Device
Lead sponsor
Magstim
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Atlanta, Georgia • Dunwoody, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 17, 2026, 12:09 PM EDT
Recruiting Not applicable Interventional

Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study

NCT07227337
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Depression, Violence
Interventions
BSHAPE, Control (general wellness)
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 12:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Addressing Mental Health of Cancer Patients and Caregivers Using a Mobile App Suite

NCT03488745
View directory record Official record
Conditions
Mental Health Wellness 1, Depression, Anxiety
Interventions
IntelliCare + Phone Coaching
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 17, 2026, 12:09 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Wright Foot & Ankle Post-Market Observational Study

NCT04118894
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis, Fracture, Trauma Injury, Fusion of Joint
Interventions
Foot and Ankle Devices
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hamilton, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 17, 2026, 12:09 PM EDT
Not yet recruiting Phase 4 Interventional

Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking

NCT07328594
View directory record Official record
Conditions
Smoking, Nicotine, Tobacco, Addiction, Substance Use Disorders, Insomnia, Sleep
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

NCT03759366
View directory record Official record
Conditions
Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Not applicable Interventional

Family-Based Treatment for Parental Substance Abuse and Child Maltreatment

NCT01656837
View directory record Official record
Conditions
Substance Abuse, Child Abuse, Child Neglect
Interventions
Comprehensive Community Treatment, MST-BSF
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New Britain, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Not applicable Interventional Results available

Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

NCT01870401
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Lutonix DCB, Uncoated PTA Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
33
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Bradenton, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 12:09 PM EDT
Active, not recruiting Phase 2 Interventional

Use of CBD in the Treatment of Anxiety

NCT06672666
View directory record Official record
Conditions
Anxiety, Generalized Anxiety Disorder, Sleep Problems
Interventions
Hemp Derived Cannabidiol Extract, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 12:09 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Using Mobile Technology to Prevent HIV and Related Youth Health Problems

NCT05130151
View directory record Official record
Conditions
HIV Infections
Interventions
Youth Health SMS
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
15 Years to 19 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 17, 2026, 12:09 PM EDT
Withdrawn Phase 2 Interventional

Omacor for Perimenopausal Depression

NCT00517972
View directory record Official record
Conditions
Depression
Interventions
Omacor (omega-3-acid ethyl esters)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 17, 2026, 12:09 PM EDT
Recruiting Phase 3 Interventional

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

NCT06247839
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Sharmin Ghaznavi
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Results available

Depakote ER in Bipolar Depression

NCT00186186
View directory record Official record
Conditions
Depression, Bipolar
Interventions
Depakote ER
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

NCT04731675
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)
Interventions
AMB-05X
Biological
Lead sponsor
AmMax Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 17, 2026, 12:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression

NCT00931619
View directory record Official record
Conditions
Epilepsy, Epilepsy, Temporal Lobe, Depression, Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 12:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

NCT03653507
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, oxaliplatin, capecitabine, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Monterey, California • Fairway, Kansas • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplementation for Bipolar Depression

NCT01884844
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression
Interventions
Vitamin D3, Cholecalciferol, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 17, 2026, 12:09 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study

NCT04482036
View directory record Official record
Conditions
Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
Interventions
Mobile Phone Application Assessments, Standard Assessments
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Not applicable Interventional Results available

Communication and Coping for Mothers of Adolescents With Type 1 Diabetes

NCT03818711
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Communication & Coping Intervention, Education & Check Ins
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 17, 2026, 12:09 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

NCT02080364
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
80
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 17, 2026, 12:09 PM EDT
Terminated Not applicable Interventional Results available

Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes

NCT03562767
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Group-based Cognitive Behavioral Intervention, Web-based Cognitive Behavioral Intervention, Usual Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 17, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

NCT02549092
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 17, 2026, 12:09 PM EDT